Previous cancer vaccine attempts using "shared antigens" failed. Moderna's success stems from creating a unique mRNA vaccine for each patient after discovering that roughly 90% of the targeted cancer antigens differ between individuals. This finding proves that a highly personalized approach is not just an edge case, but a core requirement for the therapy's efficacy.
Since every vaccine dose is unique, the FDA cannot approve each one individually. Instead, Moderna gets a "process BLA" (Biologics License Application). The key regulatory burden is proving that the same inputs (tumor/blood samples) will reliably and consistently produce the exact same output, ensuring the integrity of the end-to-end system.
The current successful vaccine uses a 10-year-old algorithm. Moderna's CEO frames it as "version 1.0," emphasizing a culture of continuous improvement. The company will now use Phase 3 trial data to mine for insights, improve the algorithm to help the 20% of non-responders, and create a "version 2.0."
To manufacture thousands of unique drugs, Moderna focuses on operational efficiency. The CEO is "obsessed" with two vectors: reducing the "needle-to-needle" cycle time (currently ~42 days) and shrinking the physical footprint of the manufacturing robots. This allows for more machines in a clean room, increasing throughput and lowering fixed costs per dose.
Unlike previous protein-based cancer vaccines that circulate in the blood, Moderna's mRNA enters antigen-presenting cells (APCs) in lymph nodes. The mRNA message is then translated inside the immune cells, presenting the cancer signature "from within." This creates a more robust and specific T-cell response, a crucial differentiator that led to success where others failed.
Moderna's strategy isn't limited to melanoma. The first prong is augmenting existing checkpoint inhibitors (like Keytruda) where they work. The second is acting as a monotherapy in early-stage disease where checkpoints are too risky. The third is entering markets where inhibitors have failed entirely, such as pancreas cancer, due to its orthogonal mechanism of action.